IP Library › Granted Patent US 12,540,196
Granted Patent B2
US 12,540,196 · App. 17/834,183 · Granted Feb 3, 2026

GPC3 binding molecules

Inventors: Matthew Drever (Concord, CA); Gabrielle M. Romain (Albany, CA); Sarah K. Wyman (Washington, DC); Chi Ying (Oakland, CA)
Assignee: Kite Pharma, Inc.
C07K16/303A61K40/11A61K40/31A61K40/4229A61K40/4261A61P35/00C07K14/7051C07K14/70517C07K14/70578A61K2239/53C07K2317/24C07K2317/33C07K2317/622C07K2317/92C07K2319/03C07K2319/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,540,196
App. No.
17/834,183
Granted
Feb 3, 2026
Kind
B2
Abstract

Provided are antibodies, fragments thereof, chimeric antigen receptors (CARs) and T cell receptors (TCRs) comprising one or more of the GPC3 binding domains disclosed herein. Provided are compositions, cells and cell therapies comprising the same. Further provided are methods of treatment.

Claims (170)

1 . An antibody that binds to human Glypican 3 (GPC3), wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain (VL), wherein the VH comprises a VH complementarity determining region (CDR) 1, a VH CDR2, and a VH CDR3 of the sequence set forth in SEQ ID NO: 3, and the VL comprises a VL CDR1, a VL CDR2, and a VL CDR3 of the sequence set forth in SEQ ID NO: 14.

2 . The antibody of claim 1 , wherein the antibody is a monospecific antibody, a bispecific antibody, a scFv, a Fab, or a F(ab′) 2 .

3 . The antibody of claim 1 , wherein the antibody is a scFv.

4 . The antibody of claim 2 , wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and the VL CDR3 comprise the sequences set forth, respectively in:

(i) SEQ ID NOs.: 5, 8, 11, 16, 19, and 22;

(ii) SEQ ID NOs.: 6, 9, 12, 17, 20, and 23; or

(iii) SEQ ID NOs.: 7, 10, 13, 18, 21, and 24.

5 . The antibody of claim 3 , wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and the VL CDR3 comprise the sequences set forth, respectively in:

(i) SEQ ID NOs.: 5, 8, 11, 16, 19, and 22;

(ii) SEQ ID NOs.: 6, 9, 12, 17, 20, and 23; or

(iii) SEQ ID NOs.: 7, 10, 13, 18, 21, and 24.

6 . The antibody of claim 2 , wherein:

(i) the VH comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 3 and the VL comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 14;

(ii) the VH comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 27 and the VL comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 29;

(iii) the VH comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 33 and the VL comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 35;

(iv) the VH comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 39 and the VL comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 41; or

(v) the VH comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 45 and the VL comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 47.

7 . The antibody of claim 3 , wherein:

(i) the VH comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 3 and the VL comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 14;

(ii) the VH comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 27 and the VL comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 29;

(iii) the VH comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 33 and the VL comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 35;

(iv) the VH comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 39 and the VL comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 41; or

(v) the VH comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 45 and the VL comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 47.

8 . The antibody of claim 5 , wherein:

(i) the VH comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 3 and the VL comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 14;

(ii) the VH comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 27 and the VL comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 29;

(iii) the VH comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 33 and the VL comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 35;

(iv) the VH comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 39 and the VL comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 41; or

(v) the VH comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 45 and the VL comprises an amino acid sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 47.

9 . The antibody of claim 2 , wherein:

(i) the VH comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 3 and the VL comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 14;

(ii) the VH comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 27 and the VL comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 29;

(iii) the VH comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 33 and the VL comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 35;

(iv) the VH comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 39 and the VL comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 41; or

(v) the VH comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 45 and the VL comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 47.

10 . The antibody of claim 3 , wherein:

(i) the VH comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 3 and the VL comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 14;

(ii) the VH comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 27 and the VL comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 29;

(iii) the VH comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 33 and the VL comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 35;

(iv) the VH comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 39 and the VL comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 41; or

(v) the VH comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 45 and the VL comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 47.

11 . The antibody of claim 5 , wherein:

(i) the VH comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 3 and the VL comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 14;

(ii) the VH comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 27 and the VL comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 29;

(iii) the VH comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 33 and the VL comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 35;

(iv) the VH comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 39 and the VL comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 41; or

(v) the VH comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 45 and the VL comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO: 47.

12 . The antibody of claim 2 , wherein:

(i) the VH comprises the sequence set forth in SEQ ID NO: 3 and the VL comprises the sequence set forth in SEQ ID NO: 14;

(ii) the VH comprises the sequence set forth in SEQ ID NO: 27 and the VL comprises the sequence set forth in SEQ ID NO: 29;

(iii) the VH comprises the sequence set forth in SEQ ID NO: 33 and the VL comprises the sequence set forth in SEQ ID NO: 35;

(iv) the VH comprises the sequence set forth in SEQ ID NO: 39 and the VL comprises the sequence set forth in SEQ ID NO: 41; or

(v) the VH comprises the sequence set forth in SEQ ID NO: 45 and the VL comprises the sequence set forth in SEQ ID NO:47.

13 . The antibody of claim 3 , wherein:

(i) the VH comprises the sequence set forth in SEQ ID NO: 3 and the VL comprises the sequence set forth in SEQ ID NO: 14;

(ii) the VH comprises the sequence set forth in SEQ ID NO: 27 and the VL comprises the sequence set forth in SEQ ID NO: 29;

(iii) the VH comprises the sequence set forth in SEQ ID NO: 33 and the VL comprises the sequence set forth in SEQ ID NO: 35;

(iv) the VH comprises the sequence set forth in SEQ ID NO: 39 and the VL comprises the sequence set forth in SEQ ID NO: 41; or

(v) the VH comprises the sequence set forth in SEQ ID NO: 45 and the VL comprises the sequence set forth in SEQ ID NO:47.

14 . The antibody of claim 5 , wherein:

(i) the VH comprises the sequence set forth in SEQ ID NO: 3 and the VL comprises the sequence set forth in SEQ ID NO: 14;

(ii) the VH comprises the sequence set forth in SEQ ID NO: 27 and the VL comprises the sequence set forth in SEQ ID NO: 29;

(iii) the VH comprises the sequence set forth in SEQ ID NO: 33 and the VL comprises the sequence set forth in SEQ ID NO: 35;

(iv) the VH comprises the sequence set forth in SEQ ID NO: 39 and the VL comprises the sequence set forth in SEQ ID NO: 41; or

(v) the VH comprises the sequence set forth in SEQ ID NO: 45 and the VL comprises the sequence set forth in SEQ ID NO:47.

15 . The antibody of claim 2 , wherein the VH comprises the sequence set forth in SEQ ID NO: 3 and the VL comprises the sequence set forth in SEQ ID NO: 14.

16 . The antibody of claim 3 , wherein the VH comprises the sequence set forth in SEQ ID NO: 3 and the VL comprises the sequence set forth in SEQ ID NO: 14.

17 . The antibody of claim 5 , wherein the VH comprises the sequence set forth in SEQ ID NO: 3 and the VL comprises the sequence set forth in SEQ ID NO: 14.

18 . The antibody of claim 3 , wherein the scFv comprises an amino acid sequence that is at least 85% identical to the sequence set forth in any one of SEQ ID NOs.: 25, 31, 37, 43, or 49.

19 . The antibody of claim 3 , wherein the scFv comprises an amino acid sequence that is at least 90% identical to the sequence set forth in any one of SEQ ID NOs.: 25, 31, 37, 43, or 49.

20 . The antibody of claim 3 , wherein the scFv comprises an amino acid sequence that is at least 95% identical to the sequence set forth in any one of SEQ ID NOs.: 25, 31, 37, 43, or 49.

21 . The antibody of claim 3 , wherein the scFv comprises the amino acid sequence set forth in any one of SEQ ID NOs.: 25, 31, 37, 43, or 49.

22 . The antibody of claim 5 , wherein the scFv comprises the amino acid sequence set forth in any one of SEQ ID NOs.: 25, 31, 37, 43, or 49.

23 . The antibody of claim 3 , wherein the scFv comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO.: 25.

24 . The antibody of claim 3 , wherein the scFv comprises the amino acid sequence set forth in SEQ ID NO.: 25.

25 . The antibody of claim 5 , wherein the scFv comprises an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO.: 25.

26 . The antibody of claim 5 , wherein the scFv comprises the amino acid sequence set forth in SEQ ID NO.: 25.

27 . A nucleic acid or nucleic acids encoding the antibody of claim 2 .

28 . A nucleic acid encoding the antibody of claim 3 .

29 . A nucleic acid encoding the antibody of claim 5 .

30 . A nucleic acid encoding the antibody of claim 26 .

31 . A vector or vectors comprising the nucleic acid or nucleic acids of claim 27 .

32 . A vector comprising the nucleic acid of claim 28 .

33 . A vector comprising the nucleic acid of claim 29 .

34 . A vector comprising the nucleic acid of claim 30 .

35 . A host cell comprising the vector or vectors of claim 31 .

36 . A host cell comprising the vector of claim 32 .

37 . A host cell comprising the vector of claim 33 .

38 . A host cell comprising the vector of claim 34 .

39 . A method of making an scFv that binds to human GPC3, the method comprising culturing the host cell of claim 38 under conditions that lead to the expression of the scFv and isolating the scFv.

40 . A chimeric antigen receptor comprising the antibody of claim 3 , a transmembrane domain, a costimulatory domain, and a signaling domain.

41 . The chimeric antigen receptor of claim 40 , wherein the transmembrane domain is from one of 4-1BB/CD137, an alpha chain of a T cell receptor, a beta chain of a T cell receptor, 2B4, CD3 epsilon, CD4, CD5, CD8 alpha, CD9, CD16, CD19, CD22, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD134, CD137, CD154, NKG2D, or a zeta chain of a T cell receptor, or any combination thereof.

42 . The chimeric antigen receptor of claim 40 , comprising from N terminal to C-terminal, the antibody, a linker, a hinge domain, the transmembrane domain, the costimulatory domain, and the signaling domain.

43 . The chimeric antigen receptor of claim 42 , wherein the hinge domain is a CD8a hinge domain, the transmembrane domain is a CD8a transmembrane domain, the costimulatory domain is a 4-1BB costimulatory domain, and the signaling domain is a CD3ζ signaling domain.

44 . A chimeric antigen receptor comprising the antibody of claim 5 , a transmembrane domain, a costimulatory domain, and a signaling domain.

45 . The chimeric antigen receptor of claim 44 , wherein the transmembrane domain is from one of 4-1BB/CD137, an alpha chain of a T cell receptor, a beta chain of a T cell receptor, 2B4, CD3 epsilon, CD4, CD5, CD8 alpha, CD9, CD16, CD19, CD22, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD134, CD137, CD154, NKG2D, or a zeta chain of a T cell receptor, or any combination thereof.

46 . The chimeric antigen receptor of claim 44 , comprising from N terminal to C-terminal, the antibody, a linker, a hinge domain, the transmembrane domain, the costimulatory domain, and the signaling domain.

47 . The chimeric antigen receptor of claim 46 , wherein the hinge domain is a CD8α hinge domain, the transmembrane domain is a CD8α transmembrane domain, the costimulatory domain is a 4-1BB costimulatory domain, and the signaling domain is a CD3ζ signaling domain.

48 . A chimeric antigen receptor comprising the antibody of claim 26 , a transmembrane domain, a costimulatory domain, and a signaling domain.

49 . The chimeric antigen receptor of claim 48 , wherein the transmembrane domain is from one of 4-1BB/CD137, an alpha chain of a T cell receptor, a beta chain of a T cell receptor, 2B4, CD3 epsilon, CD4, CD5, CD8 alpha, CD9, CD16, CD19, CD22, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD134, CD137, CD154, NKG2D, or a zeta chain of a T cell receptor, or any combination thereof.

50 . The chimeric antigen receptor of claim 48 , comprising from N terminal to C-terminal, the antibody, a linker, a hinge domain, the transmembrane domain, the costimulatory domain, and the signaling domain.

51 . The chimeric antigen receptor of claim 50 , wherein the hinge domain is a CD8α hinge domain, the transmembrane domain is a CD8α transmembrane domain, the costimulatory domain is a 4-1BB costimulatory domain, and the signaling domain is a CD3ζ signaling domain.

52 . The chimeric antigen receptor of claim 51 , wherein the CD8α hinge domain comprises an amino acid sequence that is at least 90% identical to the sequence of SEQ ID NO: 65, the CD8α transmembrane domain comprises an amino acid sequence that is at least 90% identical to the sequence of SEQ ID NO: 69, the 4-1BB costimulatory domain comprises an amino acid sequence that is at least 90% identical to the sequence of SEQ ID NO: 75, and the CD3ζ signaling domain comprises an amino acid sequence that is at least 90% identical to the sequence of SEQ ID NO: 73.

53 . The chimeric antigen receptor of claim 51 , wherein the linker is GS (SEQ ID NO:51), the CD8a hinge domain comprises the sequence of SEQ ID NO:65, the CD8a transmembrane domain comprises the sequence of SEQ ID NO: 69, the 4-IBB costimulatory domain comprises the sequence of SEQ ID NO: 75, and the CD37 signaling domain comprises the sequence of SEQ ID NO: 73.

54 . The chimeric antigen receptor of claim 48 , comprising an amino acid sequence that is at least 85% identical to a sequence set forth in any one of SEQ ID NOs.: 121, 84, 86, 88, or 90.

55 . The chimeric antigen receptor of claim 48 , comprising the amino acid sequence of a sequence set forth in any one of SEQ ID NOs.: 121, 84, 86, 88, or 90.

56 . The chimeric antigen receptor of claim 48 , comprising an amino acid sequence that is at least 90% identical to a sequence set forth in SEQ ID NO.: 86.

57 . The chimeric antigen receptor of claim 48 , comprising the amino acid sequence of SEQ ID NO.: 86.

58 . A nucleic acid comprising a nucleic acid sequence encoding the chimeric antigen receptor of claim 52 .

59 . A nucleic acid comprising a nucleic acid sequence encoding the chimeric antigen receptor of claim 53 .

60 . A nucleic acid comprising a nucleic acid sequence encoding the chimeric antigen receptor of claim 57 .

61 . The nucleic acid of claim 60 , wherein the nucleic acid further comprises to the C-terminus of the nucleic acid sequence encoding the chimeric antigen receptor a nucleic acid sequence encoding for a dominant negative TGFB Receptor (DN TGFBR), wherein the DN TGFBR comprises from N to C-terminus:

an extracellular domain (ECD) from TGFβ receptor II;

a transmembrane domain (TMD) from TGFβ receptor II, and

an intracellular domain from TGFβ receptor II lacking amino acid residues responsible for signaling and phosphorylation present in a wild type TGFβ receptor.

62 . The nucleic acid of claim 61 , further comprising a linker comprising a nucleic acid encoding a 2A peptide that links the nucleic acid sequence encoding the chimeric antigen receptor to the nucleic acid sequence encoding the DN TGFBR.

63 . The nucleic acid of claim 62 , wherein the linker comprises the sequence set forth in SEQ ID NO:118.

64 . The nucleic acid of claim 63 , wherein the DN TGFβR consists of amino acids 23 to 194 of SEQ ID NO: 98.

65 . The nucleic acid of claim 64 , comprising a nucleic acid sequence that encodes a polypeptide that is at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 90.

66 . The nucleic acid of claim 64 , comprising a nucleic acid sequence that encodes the amino acid sequence set forth in SEQ ID NO.: 113.

67 . The nucleic acid of claim 61 , wherein the nucleic acid further comprises to the C-terminus of the nucleic acid sequence encoding the DN TGFβR a nucleotide sequence encoding a membrane bound IL15-IL-15Rα sushi domain chimeric receptor.

68 . The nucleic acid of claim 67 , wherein the nucleotide sequence encoding the membrane bound IL15-IL-15Rα sushi domain chimeric receptor is separated from the nucleic acid sequence encoding for the DN TGFβR by an IRES.

69 . The nucleic acid of claim 66 , wherein the nucleic acid further comprises to the C-terminus of the nucleic acid sequence encoding the DN TGFBR a nucleotide sequence encoding a membrane bound IL15-IL-15Rα sushi domain chimeric receptor.

70 . The nucleic acid of claim 69 , wherein the nucleotide sequence encoding the membrane bound IL15-IL-15Rα sushi domain chimeric receptor is separated from the nucleic acid sequence encoding for the DN TGFβ by an IRES.

71 . A vector comprising the nucleic acid of claim 60 .

72 . A vector comprising the nucleic acid of claim 61 .

73 . A vector comprising the nucleic acid of claim 63 .

74 . A vector comprising the nucleic acid of claim 64 .

75 . A vector comprising the nucleic acid of claim 66 .

76 . A vector comprising the nucleic acid of claim 69 .

77 . A vector comprising the nucleic acid of claim 70 .

78 . A host cell comprising the vector of claim 71 .

79 . A host cell comprising the vector of claim 72 .

80 . A host cell comprising the vector of claim 73 .

81 . A host cell comprising the vector of claim 74 .

82 . A host cell comprising the vector of claim 75 .

83 . A host cell comprising the vector of claim 76 .

84 . A host cell comprising the vector of claim 77 .

85 . The host cell of claim 78 , where the host cell is a T cell or a NK cell.

86 . The host cell of claim 82 , where the host cell is a T cell or a NK cell.

87 . The host cell of claim 83 , where the host cell is a T cell or a NK cell.

88 . The host cell of claim 84 , where the host cell is a T cell or a NK cell.

89 . A pharmaceutical composition comprising the host cell of claim 85 and a pharmaceutically acceptable carrier.

90 . A pharmaceutical composition comprising the host cell of claim 86 and a pharmaceutically acceptable carrier.

91 . A pharmaceutical composition comprising the host cell of claim 87 and a pharmaceutically acceptable carrier.

92 . A pharmaceutical composition comprising the host cell of claim 88 and a pharmaceutically acceptable carrier.

93 . A method of treating hepatocellular carcinoma in a human subject in need of thereof, the method comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 89 to the human subject.

94 . A method of treating hepatocellular carcinoma in a human subject in need of thereof, the method comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 90 to the human subject.

95 . A method of treating hepatocellular carcinoma in a human subject in need of thereof, the method comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 91 to the human subject.

96 . A method of treating hepatocellular carcinoma in a human subject in need of thereof, the method comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 92 to the human subject.

97 . A method of inducing an immune response in a human subject presenting with hepatocellular carcinoma, the method comprising administering to the human subject the host cell of claim 85 .

98 . The method of claim 97 , wherein the host cell is a T cell or NK cell that is autologous to the human subject.

99 . A method of inducing an immune response in a human subject presenting with hepatocellular carcinoma, the method comprising administering to the human subject the host cell of claim 87 .

100 . The method of claim 99 , wherein the host cell is a T cell or NK cell that is autologous to the human subject.

101 . A method of inducing an immune response in a human subject presenting with hepatocellular carcinoma, the method comprising administering to the human subject the host cell of claim 88 .

102 . The method of claim 101 , wherein the host cell is a T cell or NK cell that is autologous to the human subject.

103 . A method of treating squamous cell carcinoma in a human subject in need of thereof, the method comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 89 to the human subject.

104 . The method of claim 103 , wherein the squamous cell carcinoma is non-small- cell lung carcinoma (NSCLC).

105 . A method of treating squamous cell carcinoma in a human subject in need of thereof, the method comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 90 to the human subject.

106 . The method of claim 105 , wherein the squamous cell carcinoma is NSCLC.

107 . A method of treating squamous cell carcinoma in a human subject in need of thereof, the method comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 91 to the human subject.

108 . The method of claim 107 , wherein the squamous cell carcinoma is NSCLC.

109 . A method of treating squamous cell carcinoma in a human subject in need of thereof, the method comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 92 to the human subject.

110 . The method of claim 109 , wherein the squamous cell carcinoma is NSCLC.

111 . A method of inducing an immune response in a human subject presenting with squamous cell carcinoma, the method comprising administering to the human subject the host cell of claim 85 .

112 . The method of claim 111 , wherein the host cell is a T cell or NK cell that is autologous to the human subject.

113 . A method of inducing an immune response in a human subject presenting with squamous cell carcinoma, the method comprising administering to the human subject the host cell of claim 87 .

114 . The method of claim 113 , wherein the host cell is a T cell or NK cell that is autologous to the human subject.

115 . A method of inducing an immune response in a human subject presenting with squamous cell carcinoma, the method comprising administering to the human subject the host cell of claim 88 .

116 . The method of claim 115 , wherein the host cell is a T cell or NK cell that is autologous to the human subject.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2022
From: DREVER, MATTHEW; ROMAIN, GABRIELLE M.; WYMAN, SARAH K.; YING, CHI
To: KITE PHARMA, INC.
Reel/Frame 060677/0325 →
Continuity (2)
Provisional Application 63208274 · Jun 8, 2021
Related Publication 20230020993A1 · Jan 19, 2023
References Cited (137)
US 5219740A · Miller et al. · 1993 [cited by applicant]
US 6207453B1 · Maass et al. · 2001 [cited by applicant]
US 8993524B2 · Bedi et al. · 2015 [cited by applicant]
US 9926377B2 · Polakis et al. · 2018 [cited by applicant]
US 10233258B2 · Akamatsu · 2019 [cited by examiner]
US 12109235B2 · Wyman et al. · 2024 [cited by applicant]
US 20030125251A1 · Wakefield et al. · 2003 [cited by applicant]
US 20130039911A1 · Bedi et al. · 2013 [cited by applicant]
US 20130287802A1 · Govindappa et al. · 2013 [cited by applicant]
US 20180066057A1 · Govindappa et al. · 2018 [cited by applicant]
US 20190151362A1 · Li et al. · 2019 [cited by applicant]
US 20200002402A1 · Emtage et al. · 2020 [cited by applicant]
US 20200397823A1 · Wyman et al. · 2020 [cited by applicant]
US 20230020993A1 · Drever et al. · 2023 [cited by applicant]
US 20250109182A1 · Wyman et al. · 2025 [cited by applicant]
CN 109863242A · 2019 [cited by applicant]
CN 105949324B · 2019 [cited by applicant]
EP 3569709A1 · 2019 [cited by applicant]
TW 201902929A · 2019 [cited by applicant]
WO 1993009228A1 · 1993 [cited by applicant]
WO 1994009815A1 · 1994 [cited by applicant]
WO 2003000883A1 · 2003 [cited by applicant]
WO 2004022597A1 · 2004 [cited by applicant]
WO 2011109789A2 · 2011 [cited by applicant]
WO 2012145469A1 · 2012 [cited by applicant]
WO 2013070468A1 · 2013 [cited by applicant]
WO 2013181543A1 · 2013 [cited by applicant]
WO 2014127261A1 · 2014 [cited by applicant]
WO 2014134165A1 · 2014 [cited by applicant]
WO 2014180306A1 · 2014 [cited by applicant]
WO 2015027082A1 · 2015 [cited by applicant]
WO 2015142675A2 · 2015 [cited by applicant]
WO 2015150526A2 · 2015 [cited by applicant]
WO 2015179658A2 · 2015 [cited by applicant]
WO 2016036973A1 · 2016 [cited by applicant]
WO 2016049459A1 · 2016 [cited by applicant]
WO 2016113203A1 · 2016 [cited by applicant]
WO 2016115482A1 · 2016 [cited by applicant]
WO 2017196847A1 · 2017 [cited by applicant]
WO 2018018958A1 · 2018 [cited by applicant]
WO 2018038945A1 · 2018 [cited by applicant]
WO 2018044866A1 · 2018 [cited by applicant]
WO 2018111763A1 · 2018 [cited by applicant]
WO 2018131586A1 · 2018 [cited by applicant]
WO 2018200586A1 · 2018 [cited by applicant]
WO 2018204594A1 · 2018 [cited by applicant]
WO 2019094482A1 · 2019 [cited by applicant]
WO 2019109980A1 · 2019 [cited by applicant]
WO 2020190217A2 · 2020 [cited by applicant]
WO 2021110095A1 · 2021 [cited by applicant]
Koenig P, Lee CV, Walters BT, et al. Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding. Proc Natl Acad Sci U S A. 2017;114(4):E486-… [cited by examiner]
Rabia LA, Desai AA, Jhajj HS, Tessier PM. Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility. Biochem Eng J. Sep. 15, 2018;137:365-374. (Year: 2018). [cited by examiner]
Alonso-Camino et al., “CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors” Mol. Ther. Nucleic Acids 2:e93, 2013. [cited by applicant]
Barrett et al., “Chimeric antigen receptor therapy for cancer”, Annu Rev Med (2014) 65:333-47. [cited by applicant]
Bollard, Catherine M., et al. “Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity.” Blood, The Journal of the American Society of Hematology 99.9 (2002): 3179-3187. [cited by applicant]
Boris-Lawrie et al., “Recent Advances in Retrovirus Vector Technology”, Cur. Opin. Genet. Develop. 3:102-109, 1993. [cited by applicant]
Burns et al., “Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells” Proc. Natl. Acad. Sci. U.S.A. … [cited by applicant]
Carlens et al., “Ex vivo T lymphocyte expansion for retroviral transduction”, Exp. Hematol. 28(10):1137-1146, 2000. [cited by applicant]
Cartellieri et al., “Chimeric antigen receptor-engineered T cells for immunotherapy of cancer” J Biomed Biotechnol (2010) 956304. [cited by applicant]
Cavalieri et al., “Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence”, Blood 30 102(2):497-505, 2003. [cited by applicant]
Cheadle et al., “CART cells: driving the road from the laboratory to the clinic”, Lmmunol Rev (2014) 257(1):91-106. [cited by applicant]
Chen et al., “Molecular mechanisms ofT cell co-stimulation and co-inhibition”, Nature Reviews Immunol. 13:227-242, 2013. [cited by applicant]
Cooper et al., “T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect”, Blood 101:1637-1644, 2003. [cited by applicant]
Eshhar et al., “Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoolobulin and T-cell receptors”… [cited by applicant]
Fedorov et al., “PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses”, Sci Transl Med (2013) 5(215):215ra172. [cited by applicant]
Gao, Huiping, et al. “Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular CarcinomaGPC3-Targeted CAR T Cells for HCC Treatment.” Clinical Cancer Research 20.24 (2014): 6418-6428. [cited by applicant]
Glienke et al., “Advantages and applications of CAR-expressing natural killer cells”, Front Pharmacol (2015) 6:21. [cited by applicant]
Hurton et al., “Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells”, Proc. Natl Acad Sci USA 113(48): E7788-E7797. [cited by applicant]
International Search Report, issued in PCT/US2020/070157, dated Jan. 18, 2021. [cited by applicant]
Kakarla et al., “CART cells for solid tumors: armed and ready to go?”, Cancer J (2014) 20(2):151-5. [cited by applicant]
Kershaw et al., “Supernatural T cells: genetic modification of T cells for cancer therapy”, Nature Reviews Immunol. 5(12):928-940, 2005. [cited by applicant]
Kloss, Christopher C., et al. “Dominant-negative TGF-β receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication.” Molecular therapy 26.7 (2018): 1855-1866. [cited by applicant]
Li, Wenpeng, et al. “Redirecting T cells to glypican-3 with 4-1BB zeta chimeric antigen receptors results in Th1 polarization and potent antitumor activity.” Human gene therapy 28.5 (2017): 437-448. [cited by applicant]
Miller et al., “Improved retroviral vectors for gene transfer and expression”, BioTechniques 7:980-990, 1989. [cited by applicant]
Miller, “Retrovirus packaging cells” Human Gene Therapy 1:5-14, 25 1990. [cited by applicant]
Palmer et al., “Interleukin-7 receptor signaling network: an integrated systems perspective”, Cell. Mol. Immunol. 5(2):79-89, 2008. [cited by applicant]
Park et al., “Treating cancer with genetically engineered T cells”, Trends Biotechnol. 29(11):550-557,2011. [cited by applicant]
Pegram et al., “CD28z CARs and armored CARs,” Cancer J (2014) 20(2):127-33. [cited by applicant]
Ranganathan, “Pinpointing the putative heparin/sialic acid-binding residues in the ‘sushi’ domain 7 of factor H: a molecular modeling study”, Pac. Symp Biocomput. 20 2000:155-67. [cited by applicant]
Riddell et al., “Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition,” Cancer J (2014) 20(2):141-4. [cited by applicant]
Sadelain et al., “The basic principles of chimeric antigen receptor design”, Cancer Discov (2013) 3(4):388-98. [cited by applicant]
Sadelain et al.,“The promise and potential pitfalls of chimeric antigen receptors.”, Curr. Opin. Immunol. 21(2):215-223, 2009. [cited by applicant]
Scarpa et al., “Characterization of recombinant helper retroviruses from Moloney-based vectors in ecotropic and amphotropic packaging cell lines.” Virology 180:849-852, 1991. [cited by applicant]
Shochat et al., “Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia”, Blood, 124(1): 106-110. [cited by applicant]
UniProta0a213szg2, pp. 1-6. Accessed on Oct. 27, 2022. (Year: 2022). [cited by applicant]
Verhoeyen et al., “Lentiviral vector gene transfer into human T cells”, Methods Mol. Biol. 506:97-114, 2009. [cited by applicant]
Wang et al., “Phenotypic and Functional Attributes of Lentivirus Modified CD19-specific Human CDS+ Central Memory T Cells Manufactured at Clinical Scale”, J. Immunother. 35(9):689-701, 2003. [cited by applicant]
Wieser, R., et al. “Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region.” Molecular and Cellular Biology 13.12 (1993): 7239-7247. [cited by applicant]
Yu et al., “Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma,” Molecular Therapy, vol. 26, No. 2, (2017), pp. 366-378. [cited by applicant]
Zhai, Bo, et al. “A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+ hepatocellular carcinoma (r/r GPC3+ HCC).” (2017): 3049-3049. [cited by applicant]
Jul. 25, 2019 (Jul. 25, 2019), “IL2RG fusion protein, Seq ID 27.”, retrieved from EBI accession No. GSP:BGL03586 Database accession No. BGL03586 sequence & Database Geneseq [Online]. [cited by applicant]
Jul. 25, 2019 (Jul. 25, 2019), “Human TGF-beta receptor I protein extracellular domain, Seq ID 4.”, retrieved from EBI accession No. GSP:BGL03563 Database accession No. BGL03563 Sequence. [cited by applicant]
Aug. 9, 2018 (Aug. 9, 2018), “Dominant negative TGFB-RII protein, Seq ID 97. ”, retrieved from EBI accession No. GSP:BFK39104 Database accession No. BFK39104 Sequence. [cited by applicant]
May 3, 2018 (May 3, 2018), “Cixutumumab light chain-TGF-beta RII ECO fusion protein.”, retrieved from EBI accession No. GSP:BFD37600 Database accession No. BFD37600 Sequence. [cited by applicant]
Hurton Lenka V., et al. “Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells.” Proceedings of the National Academy of Sciences, Nov. 14, 2016, p. E7788-E7797, vol.… [cited by applicant]
Shochat Chen, et al. “Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia.” Blood, The Journal of the American Society of Hematology, Jul. 3, 2014, p. 106-110, vol. 1… [cited by applicant]
International Search Report issued in PCT/US2022/032455, dated Oct. 5, 2022. [cited by applicant]
Bendle, Gavin M., et al. “Blockade of TGF-β signaling greatly enhances the efficacy of TCR gene therapy of cancer.” The Journal of Immunology 191.6 (2013): 3232-3239. [cited by applicant]
Ishiguro, Takahiro, et al. “Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.” Cancer research 68.23 (2008): 9832-9838. [cited by applicant]
Phung, Yen, et al. “High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening.” MAbs. vol. 4. No. 5. Taylor & Franc… [cited by applicant]
Vong, Queenie, et al. “Inhibiting TGFβ signaling in CAR T-cells may significantly enhance efficacy of tumor Immunotherapy.” Blood 130 (2017): 1791. [cited by applicant]
Zhang, Yi-Fan, and Mitchell Ho. “Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma.” Scientific reports 6.1 (2016): 1-11. [cited by applicant]
Fabregat et al., “TGF-beta signaling in cancer treatment,” Current pharmaceutical design, May 1, 2014, 20(17):2934-47. [cited by applicant]
GenBank Accession No. NM_003242.5, “ [cited by applicant]
Heldin et al., “Signaling receptors for TGF-β family members,” Cold Spring Harbor perspectives in biology, Aug. 1, 2016, 8(8):a022053. [cited by applicant]
Inman et al., “Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-β receptor activity,” Molecular cell, Aug. 1, 2002, 10(2):283-94. [cited by applicant]
International Preliminary Report in International Appln. No. Patentability PCT/US2020/070157, mailed on Dec. 30, 2021, 13 pages. [cited by applicant]
Office Action in Australian Appln. No. 2020296878, dated Nov. 17, 2022, 3 pages. [cited by applicant]
Office Action in Australian Appln. No. 2023206126, dated Aug. 28, 2024, 3 pages. [cited by applicant]
Office Action in Canadian Appln. No. 3143271, dated Apr. 29, 2024, 6 pages. [cited by applicant]
Office Action in Canadian Appln. No. 3143271, dated Jan. 25, 2023, 5 pages. [cited by applicant]
Office Action in Chinese Appln. No. 202080052340.2, dated Apr. 22, 2025, 12 pages (with English translation). [cited by applicant]
Office Action in Chinese Appln. No. 202080052340.2, dated Aug. 15, 2024, 16 pages (with English translation). [cited by applicant]
Office Action in Chinese Appln. No. 202080052340.2, dated Jan. 13, 2025, 11 pages (with English translation). [cited by applicant]
Office Action in Chinese Appln. No. 202080052340.2, dated Mar. 25, 2024, 16 pages (with English translation). [cited by applicant]
Office Action in Egyptian Appln. No. PCT2023/2021, dated Apr. 25, 2025, 11 pages (with English translation). [cited by applicant]
Office Action in EP Appln No. 20737860.5 dated Jun. 25, 2025, 5 pages. [cited by applicant]
Office Action in Eurasian Appln. No. 202393559, mailed on Jan. 15, 2025, 6 pages (with English translation). [cited by applicant]
Office Action in Japanese Appln. No. 2021-575501, mailed on Aug. 1, 2023, 10 pages (with English translation). [cited by applicant]
Office Action in Japanese Appln. No. 2021-575501, mailed on dated Feb. 19, 2024, 5 pages (with English translation). [cited by applicant]
Office Action in Japanese Appln. No. 2021-575501, mailed on Feb. 7, 2023, 16 pages (with English translation). [cited by applicant]
Office Action in Korean Appln. No. 10-2022-7001748, dated Feb. 25, 2025, 10 pages (with English translation). [cited by applicant]
Office Action in Korean Appln. No. 10-2022-7001748, dated Jun. 26, 2024, 18 pages (with English translation). [cited by applicant]
Office Action in Mexican Appln. No. MX/a/2021/015451, dated May 24, 2024, 10 pages (with machine English translation). [cited by applicant]
Office Action in New Zealand Appln. No. 783560, dated Feb. 13, 2025, 6 pages. [cited by applicant]
Office Action in New Zealand Appln. No. 783560, dated Jul. 29, 2024, 4 pages. [cited by applicant]
Office Action in Saudi Arabian Appln. No. 521431148, dated Jun. 13, 2024, 12 pages (with English translation). [cited by applicant]
Office Action in Saudi Arabian Appln. No. 521431148, dated Mar. 26, 2023, 17 pages (with machine English translation). [cited by applicant]
Office Action in Singaporean Appln. No. 11202113969Y, dated Mar. 13, 2023, 7 pages. [cited by applicant]
Office Action in Taiwanese Appln. No 111121144, mailed Jul. 24, 2023, 10 pages (with English translation). [cited by applicant]
Office Action in Taiwanese Appln. No. 109121004, dated May 31, 2024, 10 pages (with English translation). [cited by applicant]
Office Action in United Arab Emirates Appln. No. P6002352/2021, dated Oct. 10, 2024, 11 pages. [cited by applicant]
Office Action, issued in TW Application No. 108121854, dated Nov. 3, 2020. [cited by applicant]
Pickup et al., “The roles of TGFβ in the tumour microenvironment,” Nature Reviews Cancer, Nov. 2013, 13(11):788-99. [cited by applicant]
Thomas et al., “TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance,” Cancer cell, Nov. 1, 2005, 8(5):369-80. [cited by applicant]
Wieser et al., “Signaling activity of transforming growth factor β type II receptors lacking specific domains in the cytoplasmic region,” Molecular and cellular biology, Dec. 1, 1993, 13(12): 7239-47. [cited by applicant]
Yang et al., “TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression,” Trends in immunology, Jun. 1, 2010, 31(6):220-7. [cited by applicant]